Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients

Shizuma Omote, Katsuyoshi Takata, Takehiro Tanaka, Tomoko Miyata-Takata, Yoshiyuki Ayada, Mai Noujima-Harada, Rika Omote, Tetsuya Tabata, Yasuharu Sato, Tatsuya Toyokawa, Hironari Katou, Takahito Yagi, Hiroyuki Okada, Tadashi Yoshino

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37%). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12–3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalMedical Molecular Morphology
DOIs
Publication statusAccepted/In press - Jun 20 2018

Fingerprint

Folate Receptor 1
Pancreatic Neoplasms
Tumor Biomarkers
Disease-Free Survival
Down-Regulation
Biomarkers

Keywords

  • CA19-9
  • Folate receptor alpha
  • FR-α
  • Pancreatic cancer
  • Prognostic markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology

Cite this

Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. / Omote, Shizuma; Takata, Katsuyoshi; Tanaka, Takehiro; Miyata-Takata, Tomoko; Ayada, Yoshiyuki; Noujima-Harada, Mai; Omote, Rika; Tabata, Tetsuya; Sato, Yasuharu; Toyokawa, Tatsuya; Katou, Hironari; Yagi, Takahito; Okada, Hiroyuki; Yoshino, Tadashi.

In: Medical Molecular Morphology, 20.06.2018, p. 1-7.

Research output: Contribution to journalArticle

@article{fc33085afc5c48778b1297f90f58ff01,
title = "Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients",
abstract = "Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37{\%}). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12–3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.",
keywords = "CA19-9, Folate receptor alpha, FR-α, Pancreatic cancer, Prognostic markers",
author = "Shizuma Omote and Katsuyoshi Takata and Takehiro Tanaka and Tomoko Miyata-Takata and Yoshiyuki Ayada and Mai Noujima-Harada and Rika Omote and Tetsuya Tabata and Yasuharu Sato and Tatsuya Toyokawa and Hironari Katou and Takahito Yagi and Hiroyuki Okada and Tadashi Yoshino",
year = "2018",
month = "6",
day = "20",
doi = "10.1007/s00795-018-0197-8",
language = "English",
pages = "1--7",
journal = "Medical Electron Microscopy",
issn = "0918-4287",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients

AU - Omote, Shizuma

AU - Takata, Katsuyoshi

AU - Tanaka, Takehiro

AU - Miyata-Takata, Tomoko

AU - Ayada, Yoshiyuki

AU - Noujima-Harada, Mai

AU - Omote, Rika

AU - Tabata, Tetsuya

AU - Sato, Yasuharu

AU - Toyokawa, Tatsuya

AU - Katou, Hironari

AU - Yagi, Takahito

AU - Okada, Hiroyuki

AU - Yoshino, Tadashi

PY - 2018/6/20

Y1 - 2018/6/20

N2 - Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37%). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12–3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.

AB - Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37%). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12–3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.

KW - CA19-9

KW - Folate receptor alpha

KW - FR-α

KW - Pancreatic cancer

KW - Prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=85048835222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048835222&partnerID=8YFLogxK

U2 - 10.1007/s00795-018-0197-8

DO - 10.1007/s00795-018-0197-8

M3 - Article

C2 - 29926190

AN - SCOPUS:85048835222

SP - 1

EP - 7

JO - Medical Electron Microscopy

JF - Medical Electron Microscopy

SN - 0918-4287

ER -